Literature DB >> 23582152

Diminished neurokinin-1 receptor availability in patients with two forms of chronic visceral pain.

Johanna M Jarcho1, Natasha A Feier, Alberto Bert, Jennifer A Labus, Maunoo Lee, Jean Stains, Bahar Ebrat, Stephanie M Groman, Kirsten Tillisch, Arthur L Brody, Edythe D London, Mark A Mandelkern, Emeran A Mayer.   

Abstract

Central sensitization and dysregulation of peripheral <span class="Gene">substance P and <span class="Gene">neurokinin-1 receptor (NK-1R) signaling are associated with chronic abdominal pain in inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). Although positron emission tomography (PET) has demonstrated that patients with injury-related chronic pain have diminished NK-1R availability in the brain, it is unknown whether these deficits are present in IBD and IBS patients, who have etiologically distinct forms of non-injury-related chronic pain. This study's aim was to determine if patients with IBD or IBS exhibit deficits in brain expression of NK-1Rs relative to healthy controls (HCs), the extent to which expression patterns differ across patient populations, and if these patterns differentially relate to clinical parameters. PET with [(18)F]SPA-RQ was used to measure NK-1R availability by quantifying binding potential (BP) in the 3 groups. Exploratory correlation analyses were performed to detect associations between NK-1R BP and physical symptoms. Compared to HCs, IBD patients had NK-1R BP deficits across a widespread network of cortical and subcortical regions. IBS patients had similar, but less pronounced deficits. BP in a subset of these regions was robustly related to discrete clinical parameters in each patient population. Widespread deficits in NK-1R BP occur in IBD and, to a lesser extent, IBS; however, discrete clinical parameters relate to NK-1R BP in each patient population. This suggests that potential pharmacological interventions that target NK-1R signaling may be most effective for treating distinct symptoms in IBD and IBS.
Copyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23582152      PMCID: PMC4294187          DOI: 10.1016/j.pain.2013.02.026

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  79 in total

1.  Human biodistribution and radiation dosimetry of the tachykinin NK1 antagonist radioligand [18F]SPA-RQ: comparison of thin-slice, bisected, and 2-dimensional planar image analysis.

Authors:  David R Sprague; Frederick T Chin; Jeih-San Liow; Masahiro Fujita; H Donald Burns; Richard Hargreaves; James B Stubbs; Victor W Pike; Robert B Innis; P David Mozley
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 2.  Neurobiology of emotion perception I: The neural basis of normal emotion perception.

Authors:  Mary L Phillips; Wayne C Drevets; Scott L Rauch; Richard Lane
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

3.  Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder.

Authors:  David Michelson; Richard Hargreaves; Robert Alexander; Paulette Ceesay; Jarmo Hietala; Christopher Lines; Scott Reines
Journal:  Int J Neuropsychopharmacol       Date:  2012-03-20       Impact factor: 5.176

4.  Spinal NK1 receptor is upregulated after chronic bladder irritation.

Authors:  Manabu Ishigooka; Dirk-Henrik Zermann; Ragi Doggweiler; Richard A Schmidt; Tohru Hashimoto; Teruhiro Nakada
Journal:  Pain       Date:  2001-07       Impact factor: 6.961

5.  A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus.

Authors:  Claire Roberts; Amir Inamdar; Annelize Koch; Pauline Kitchiner; Odile Dewit; Emilio Merlo-Pich; Paolo Fina; Don J McFerran; David M Baguley
Journal:  Otol Neurotol       Date:  2011-07       Impact factor: 2.311

6.  Gender and age affect NK1 receptors in the human brain - a positron emission tomography study with [18F]SPA-RQ.

Authors:  Mikko J Nyman; Olli Eskola; Jaana Kajander; Tero Vahlberg; Sandra Sanabria; Donald Burns; Richard Hargreaves; Olof Solin; Jarmo Hietala
Journal:  Int J Neuropsychopharmacol       Date:  2006-03-30       Impact factor: 5.176

7.  Pain processing in four regions of human cingulate cortex localized with co-registered PET and MR imaging.

Authors:  B A Vogt; S Derbyshire; A K Jones
Journal:  Eur J Neurosci       Date:  1996-07       Impact factor: 3.386

8.  Decreased neurokinin-1 (substance P) receptor binding in patients with panic disorder: positron emission tomographic study with [18F]SPA-RQ.

Authors:  Yota Fujimura; Fumihiko Yasuno; Amanda Farris; Jeih-San Liow; Marilla Geraci; Wayne Drevets; Daniel S Pine; Subroto Ghose; Alicja Lerner; Richard Hargreaves; H Donald Burns; Cheryl Morse; Victor W Pike; Robert B Innis
Journal:  Biol Psychiatry       Date:  2009-02-07       Impact factor: 13.382

9.  Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain.

Authors:  Wei Guo; Hu Wang; Mineo Watanabe; Kohei Shimizu; Shiping Zou; Stacey C LaGraize; Feng Wei; Ronald Dubner; Ke Ren
Journal:  J Neurosci       Date:  2007-05-30       Impact factor: 6.167

Review 10.  Role of neuropeptides in inflammatory bowel disease.

Authors:  Kara J Gross; Charalabos Pothoulakis
Journal:  Inflamm Bowel Dis       Date:  2007-07       Impact factor: 5.325

View more
  10 in total

Review 1.  Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.

Authors:  Martin S Steinhoff; Bengt von Mentzer; Pierangelo Geppetti; Charalabos Pothoulakis; Nigel W Bunnett
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 2.  Supraspinal Mechanisms of Intestinal Hypersensitivity.

Authors:  Olga A Lyubashina; Ivan B Sivachenko; Sergey S Panteleev
Journal:  Cell Mol Neurobiol       Date:  2020-10-08       Impact factor: 5.046

3.  Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.

Authors:  Dane D Jensen; TinaMarie Lieu; Michelle L Halls; Nicholas A Veldhuis; Wendy L Imlach; Quynh N Mai; Daniel P Poole; Tim Quach; Luigi Aurelio; Joshua Conner; Carmen Klein Herenbrink; Nicholas Barlow; Jamie S Simpson; Martin J Scanlon; Bimbil Graham; Adam McCluskey; Phillip J Robinson; Virginie Escriou; Romina Nassini; Serena Materazzi; Pierangelo Geppetti; Gareth A Hicks; Macdonald J Christie; Christopher J H Porter; Meritxell Canals; Nigel W Bunnett
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

4.  Honokiol for the Treatment of Neonatal Pain and Prevention of Consequent Neurobehavioral Disorders.

Authors:  Anna Woodbury; Shan Ping Yu; Dongdong Chen; Xiaohuan Gu; Jin Hwan Lee; James Zhang; Alyssa Espinera; Paul S García; Ling Wei
Journal:  J Nat Prod       Date:  2015-11-05       Impact factor: 4.050

5.  Regional neuroplastic brain changes in patients with chronic inflammatory and non-inflammatory visceral pain.

Authors:  Jui-Yang Hong; Jennifer S Labus; Zhiguo Jiang; Cody Ashe-Mcnalley; Ivo Dinov; Arpana Gupta; Yonggang Shi; Jean Stains; Nuwanthi Heendeniya; Suzanne R Smith; Kirsten Tillisch; Emeran A Mayer
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

6.  Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response.

Authors:  Johanna M Jarcho; Natasha A Feier; Jennifer S Labus; Bruce Naliboff; Suzanne R Smith; Jui-Yang Hong; Luana Colloca; Kirsten Tillisch; Mark A Mandelkern; Emeran A Mayer; Edythe D London
Journal:  Neuroimage Clin       Date:  2015-11-14       Impact factor: 4.881

Review 7.  Role of brain imaging in disorders of brain-gut interaction: a Rome Working Team Report.

Authors:  Emeran A Mayer; Jennifer Labus; Qasim Aziz; Irene Tracey; Lisa Kilpatrick; Sigrid Elsenbruch; Petra Schweinhardt; Lukas Van Oudenhove; David Borsook
Journal:  Gut       Date:  2019-06-07       Impact factor: 23.059

8.  The Neuropeptide-Related HERC5/TAC1 Interactions May Be Associated with the Dysregulation of lncRNA GAS5 Expression in Gestational Diabetes Mellitus Exosomes.

Authors:  Gui-Yan Tang; Ping Yu; Chen Zhang; Hong-Yu Deng; Mei-Xiu Lu; Jiang-Hua Le
Journal:  Dis Markers       Date:  2022-02-08       Impact factor: 3.434

9.  Pain-related mediators underlie incision-induced mechanical nociception in the dorsal root ganglia.

Authors:  Xiuhong Yuan; Xiangyan Liu; Qiuping Tang; Yunlong Deng
Journal:  Neural Regen Res       Date:  2013-12-15       Impact factor: 5.135

10.  Long-term upregulation of cortical glutamatergic AMPA receptors in a mouse model of chronic visceral pain.

Authors:  Shui-Bing Liu; Ming-Ming Zhang; Lin-Feng Cheng; Jiao Shi; Jing-Shan Lu; Min Zhuo
Journal:  Mol Brain       Date:  2015-11-19       Impact factor: 4.041

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.